Evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy followed by pembrolizumab adjuvant in stage IIA-IIIB (N2) NSCLC participants without sensitizing e.g.FR/ALK mutation using scRNA-seq. Here, ALK is linked to non-small cell lung carcinoma.